Literature DB >> 22645997

[Changes in plasmic and platelet hemostasis in patients with chronic renal failure in hemodialysis].

M S Surovikina, V V Samoĭlenko, E A Vlasova, I A Vasilenko, V P Suslov.   

Abstract

Plasmic and platelet components of hemostasis were examined in 50 patients with terminal chronic renal failure (CRF) aged 23 to 67 years and 30 healthy controls of the same age. A plasmic hemostasis component was studied basing on 11 parameters of coagulogram. A platelet hemostasis component was studied by platelet aggregation: spontaneous and induced by ADP (in concentration 1.25, 2.5 and 5.0 mkg/ml), collagen, adrenalin and ristomycin. All CRF patients before hemodialysis had a significant alterations of 6 indices of a plasmic component of hemostasis: activated partial thromboplastic time, content of soluble fibrinmonomeric complexes, thrombine time; of 3 from 7 tests of aggregatogram (ADP, collagen, ristomycin induced aggregation). After hemodialysis severity of the above pathological shifts deteriorated (1.5 to 5 times). Thus, CRF patients on hemodialysis showed aggrevation of impairment of all hemostasis components. They are at risk of hypercoagulation, DIC-syndrome, massive thromboembolism. The above impairment of hemostasis should be considered in prescription of anticoagulant therapy to CRF patients. Monitoring of hemodialysis and adequate correction of the hemostasis system defects may contribute to improvement of quality of life of patients with terminal CRF and lowering of their mortality rate.

Entities:  

Mesh:

Year:  2012        PMID: 22645997

Source DB:  PubMed          Journal:  Urologiia        ISSN: 1728-2985


  1 in total

1.  Impact of increased inflammation biomarkers on periprocedural myocardial infarction in patients undergoing elective percutaneous coronary intervention: a cohort study.

Authors:  Liding Zhao; Ya Li; Tian Xu; Yi Luan; Qingbo Lv; Yao Wang; Xue Lv; Guosheng Fu; Wenbin Zhang
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 2.895

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.